1.1Senator López Franzen moved to amend
S.F. No. 4410 as follows:
1.2Page 381, after line 2, insert:
1.3 "Sec. 26. Minnesota Statutes 2020, section 152.01, subdivision 23, is amended to read:
1.4 Subd. 23.
Analog. (a) Except as provided in paragraph (b), "analog" means a substance,
1.5the chemical structure of which is substantially similar to the chemical structure
of a
1.6controlled substance in Schedule I or II:
1.7(1) that has a stimulant, depressant, or hallucinogenic effect on the central nervous
system
1.8that is substantially similar to or greater than the stimulant, depressant, or hallucinogenic
1.9effect on the central nervous system of a controlled substance in Schedule I or II;
or
1.10(2) with respect to a particular person, if the person represents or intends that
the substance
1.11have a stimulant, depressant, or hallucinogenic effect on the central nervous system
that is
1.12substantially similar to or greater than the stimulant, depressant, or hallucinogenic
effect
1.13on the central nervous system of a controlled substance in Schedule I or II.
1.14(b) "Analog" does not include:
1.15(1) a controlled substance;
1.16(2) any substance for which there is an approved new drug application under the Federal
1.17Food, Drug, and Cosmetic Act;
or
1.18(3) with respect to a particular person, any substance, if an exemption is in effect
for
1.19investigational use, for that person, as provided by United States Code, title 21,
section 355,
1.20and the person is registered as a controlled substance researcher as required under
section
1.21152.12, subdivision 3, to the extent conduct with respect to the substance is pursuant to the
1.22exemption and registration
; or
1.23(4) marijuana or tetrahydrocannabinols naturally contained in a plant of the genus
1.24cannabis or in the resinous extractives of the plant.
1.25EFFECTIVE DATE.This section is effective August 1, 2022, and applies to crimes
1.26committed on or after that date.
1.27 Sec. 27. Minnesota Statutes 2020, section 152.02, subdivision 2, is amended to read:
1.28 Subd. 2.
Schedule I. (a) Schedule I consists of the substances listed in this subdivision.
1.29(b) Opiates. Unless specifically excepted or unless listed in another schedule, any
of the
1.30following substances, including their analogs, isomers, esters, ethers, salts, and
salts of
2.1isomers, esters, and ethers, whenever the existence of the analogs, isomers, esters,
ethers,
2.2and salts is possible:
2.3(1) acetylmethadol;
2.4(2) allylprodine;
2.5(3) alphacetylmethadol (except levo-alphacetylmethadol, also known as levomethadyl
2.6acetate);
2.7(4) alphameprodine;
2.8(5) alphamethadol;
2.9(6) alpha-methylfentanyl benzethidine;
2.10(7) betacetylmethadol;
2.11(8) betameprodine;
2.12(9) betamethadol;
2.13(10) betaprodine;
2.14(11) clonitazene;
2.15(12) dextromoramide;
2.16(13) diampromide;
2.17(14) diethyliambutene;
2.18(15) difenoxin;
2.19(16) dimenoxadol;
2.20(17) dimepheptanol;
2.21(18) dimethyliambutene;
2.22(19) dioxaphetyl butyrate;
2.23(20) dipipanone;
2.24(21) ethylmethylthiambutene;
2.25(22) etonitazene;
2.26(23) etoxeridine;
2.27(24) furethidine;
2.28(25) hydroxypethidine;
3.1(26) ketobemidone;
3.2(27) levomoramide;
3.3(28) levophenacylmorphan;
3.4(29) 3-methylfentanyl;
3.5(30) acetyl-alpha-methylfentanyl;
3.6(31) alpha-methylthiofentanyl;
3.7(32) benzylfentanyl beta-hydroxyfentanyl;
3.8(33) beta-hydroxy-3-methylfentanyl;
3.9(34) 3-methylthiofentanyl;
3.10(35) thenylfentanyl;
3.11(36) thiofentanyl;
3.12(37) para-fluorofentanyl;
3.13(38) morpheridine;
3.14(39) 1-methyl-4-phenyl-4-propionoxypiperidine;
3.15(40) noracymethadol;
3.16(41) norlevorphanol;
3.17(42) normethadone;
3.18(43) norpipanone;
3.19(44) 1-(2-phenylethyl)-4-phenyl-4-acetoxypiperidine (PEPAP);
3.20(45) phenadoxone;
3.21(46) phenampromide;
3.22(47) phenomorphan;
3.23(48) phenoperidine;
3.24(49) piritramide;
3.25(50) proheptazine;
3.26(51) properidine;
3.27(52) propiram;
4.1(53) racemoramide;
4.2(54) tilidine;
4.3(55) trimeperidine;
4.4(56) N-(1-Phenethylpiperidin-4-yl)-N-phenylacetamide (acetyl fentanyl);
4.5(57) 3,4-dichloro-N-[(1R,2R)-2-(dimethylamino)cyclohexyl]-N-
4.6methylbenzamide(U47700);
4.7(58) N-phenyl-N-[1-(2-phenylethyl)piperidin-4-yl]furan-2-carboxamide(furanylfentanyl);
4.8(59) 4-(4-bromophenyl)-4-dimethylamino-1-phenethylcyclohexanol (bromadol);
4.9(60) N-(1-phenethylpiperidin-4-yl)-N-phenylcyclopropanecarboxamide (Cyclopropryl
4.10fentanyl);
4.11(61) N-(1-phenethylpiperidin-4-yl)-N-phenylbutanamide) (butyryl fentanyl);
4.12(62) 1-cyclohexyl-4-(1,2-diphenylethyl)piperazine) (MT-45);
4.13(63) N-(1-phenethylpiperidin-4-yl)-N-phenylcyclopentanecarboxamide (cyclopentyl
4.14fentanyl);
4.15(64) N-(1-phenethylpiperidin-4-yl)-N-phenylisobutyramide (isobutyryl fentanyl);
4.16(65) N-(1-phenethylpiperidin-4-yl)-N-phenylpentanamide (valeryl fentanyl);
4.17(66) N-(4-chlorophenyl)-N-(1-phenethylpiperidin-4-yl)isobutyramide
4.18(para-chloroisobutyryl fentanyl);
4.19(67) N-(4-fluorophenyl)-N-(1-phenethylpiperidin-4-yl)butyramide (para-fluorobutyryl
4.20fentanyl);
4.21(68) N-(4-methoxyphenyl)-N-(1-phenethylpiperidin-4-yl)butyramide
4.22(para-methoxybutyryl fentanyl);
4.23(69) N-(2-fluorophenyl)-2-methoxy-N-(1-phenethylpiperidin-4-yl)acetamide (ocfentanil);
4.24(70) N-(4-fluorophenyl)-N-(1-phenethylpiperidin-4-yl)isobutyramide (4-fluoroisobutyryl
4.25fentanyl or para-fluoroisobutyryl fentanyl);
4.26(71) N-(1-phenethylpiperidin-4-yl)-N-phenylacrylamide (acryl fentanyl or
4.27acryloylfentanyl);
4.28(72) 2-methoxy-N-(1-phenethylpiperidin-4-yl)-N-phenylacetamide (methoxyacetyl
4.29fentanyl);
5.1(73) N-(2-fluorophenyl)-N-(1-phenethylpiperidin-4-yl)propionamide (ortho-fluorofentanyl
5.2or 2-fluorofentanyl);
5.3(74) N-(1-phenethylpiperidin-4-yl)-N-phenyltetrahydrofuran-2-carboxamide
5.4(tetrahydrofuranyl fentanyl); and
5.5(75) Fentanyl-related substances, their isomers, esters, ethers, salts and salts of
isomers,
5.6esters and ethers, meaning any substance not otherwise listed under another federal
5.7Administration Controlled Substance Code Number or not otherwise listed in this section,
5.8and for which no exemption or approval is in effect under section 505 of the Federal
Food,
5.9Drug, and Cosmetic Act, United States Code , title 21, section 355, that is structurally
related
5.10to fentanyl by one or more of the following modifications:
5.11(i) replacement of the phenyl portion of the phenethyl group by any monocycle, whether
5.12or not further substituted in or on the monocycle;
5.13(ii) substitution in or on the phenethyl group with alkyl, alkenyl, alkoxyl, hydroxyl,
halo,
5.14haloalkyl, amino, or nitro groups;
5.15(iii) substitution in or on the piperidine ring with alkyl, alkenyl, alkoxyl, ester,
ether,
5.16hydroxyl, halo, haloalkyl, amino, or nitro groups;
5.17(iv) replacement of the aniline ring with any aromatic monocycle whether or not further
5.18substituted in or on the aromatic monocycle; or
5.19(v) replacement of the N-propionyl group by another acyl group.
5.20(c) Opium derivatives. Any of the following substances, their analogs, salts, isomers,
5.21and salts of isomers, unless specifically excepted or unless listed in another schedule,
5.22whenever the existence of the analogs, salts, isomers, and salts of isomers is possible:
5.23(1) acetorphine;
5.24(2) acetyldihydrocodeine;
5.25(3) benzylmorphine;
5.26(4) codeine methylbromide;
5.27(5) codeine-n-oxide;
5.28(6) cyprenorphine;
5.29(7) desomorphine;
5.30(8) dihydromorphine;
6.1(9) drotebanol;
6.2(10) etorphine;
6.3(11) heroin;
6.4(12) hydromorphinol;
6.5(13) methyldesorphine;
6.6(14) methyldihydromorphine;
6.7(15) morphine methylbromide;
6.8(16) morphine methylsulfonate;
6.9(17) morphine-n-oxide;
6.10(18) myrophine;
6.11(19) nicocodeine;
6.12(20) nicomorphine;
6.13(21) normorphine;
6.14(22) pholcodine; and
6.15(23) thebacon.
6.16(d) Hallucinogens. Any material, compound, mixture or preparation which contains any
6.17quantity of the following substances, their analogs, salts, isomers (whether optical,
positional,
6.18or geometric), and salts of isomers, unless specifically excepted or unless listed
in another
6.19schedule, whenever the existence of the analogs, salts, isomers, and salts of isomers
is
6.20possible:
6.21(1) methylenedioxy amphetamine;
6.22(2) methylenedioxymethamphetamine;
6.23(3) methylenedioxy-N-ethylamphetamine (MDEA);
6.24(4) n-hydroxy-methylenedioxyamphetamine;
6.25(5) 4-bromo-2,5-dimethoxyamphetamine (DOB);
6.26(6) 2,5-dimethoxyamphetamine (2,5-DMA);
6.27(7) 4-methoxyamphetamine;
6.28(8) 5-methoxy-3, 4-methylenedioxyamphetamine;
7.1(9) alpha-ethyltryptamine;
7.2(10) bufotenine;
7.3(11) diethyltryptamine;
7.4(12) dimethyltryptamine;
7.5(13) 3,4,5-trimethoxyamphetamine;
7.6(14) 4-methyl-2, 5-dimethoxyamphetamine (DOM);
7.7(15) ibogaine;
7.8(16) lysergic acid diethylamide (LSD);
7.9(17) mescaline;
7.10(18) parahexyl;
7.11(19) N-ethyl-3-piperidyl benzilate;
7.12(20) N-methyl-3-piperidyl benzilate;
7.13(21) psilocybin;
7.14(22) psilocyn;
7.15(23) tenocyclidine (TPCP or TCP);
7.16(24) N-ethyl-1-phenyl-cyclohexylamine (PCE);
7.17(25) 1-(1-phenylcyclohexyl) pyrrolidine (PCPy);
7.18(26) 1-[1-(2-thienyl)cyclohexyl]-pyrrolidine (TCPy);
7.19(27) 4-chloro-2,5-dimethoxyamphetamine (DOC);
7.20(28) 4-ethyl-2,5-dimethoxyamphetamine (DOET);
7.21(29) 4-iodo-2,5-dimethoxyamphetamine (DOI);
7.22(30) 4-bromo-2,5-dimethoxyphenethylamine (2C-B);
7.23(31) 4-chloro-2,5-dimethoxyphenethylamine (2C-C);
7.24(32) 4-methyl-2,5-dimethoxyphenethylamine (2C-D);
7.25(33) 4-ethyl-2,5-dimethoxyphenethylamine (2C-E);
7.26(34) 4-iodo-2,5-dimethoxyphenethylamine (2C-I);
7.27(35) 4-propyl-2,5-dimethoxyphenethylamine (2C-P);
8.1(36) 4-isopropylthio-2,5-dimethoxyphenethylamine (2C-T-4);
8.2(37) 4-propylthio-2,5-dimethoxyphenethylamine (2C-T-7);
8.3(38) 2-(8-bromo-2,3,6,7-tetrahydrofuro [2,3-f][1]benzofuran-4-yl)ethanamine
8.4(2-CB-FLY);
8.5(39) bromo-benzodifuranyl-isopropylamine (Bromo-DragonFLY);
8.6(40) alpha-methyltryptamine (AMT);
8.7(41) N,N-diisopropyltryptamine (DiPT);
8.8(42) 4-acetoxy-N,N-dimethyltryptamine (4-AcO-DMT);
8.9(43) 4-acetoxy-N,N-diethyltryptamine (4-AcO-DET);
8.10(44) 4-hydroxy-N-methyl-N-propyltryptamine (4-HO-MPT);
8.11(45) 4-hydroxy-N,N-dipropyltryptamine (4-HO-DPT);
8.12(46) 4-hydroxy-N,N-diallyltryptamine (4-HO-DALT);
8.13(47) 4-hydroxy-N,N-diisopropyltryptamine (4-HO-DiPT);
8.14(48) 5-methoxy-N,N-diisopropyltryptamine (5-MeO-DiPT);
8.15(49) 5-methoxy-α-methyltryptamine (5-MeO-AMT);
8.16(50) 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT);
8.17(51) 5-methylthio-N,N-dimethyltryptamine (5-MeS-DMT);
8.18(52) 5-methoxy-N-methyl-N-isopropyltryptamine (5-MeO-MiPT);
8.19(53) 5-methoxy-α-ethyltryptamine (5-MeO-AET);
8.20(54) 5-methoxy-N,N-dipropyltryptamine (5-MeO-DPT);
8.21(55) 5-methoxy-N,N-diethyltryptamine (5-MeO-DET);
8.22(56) 5-methoxy-N,N-diallyltryptamine (5-MeO-DALT);
8.23(57) methoxetamine (MXE);
8.24(58) 5-iodo-2-aminoindane (5-IAI);
8.25(59) 5,6-methylenedioxy-2-aminoindane (MDAI);
8.26(60) 2-(4-bromo-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine (25B-NBOMe);
8.27(61) 2-(4-chloro-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine (25C-NBOMe);
9.1(62) 2-(4-iodo-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine (25I-NBOMe);
9.2(63) 2-(2,5-Dimethoxyphenyl)ethanamine (2C-H);
9.3(64) 2-(4-Ethylthio-2,5-dimethoxyphenyl)ethanamine (2C-T-2);
9.4(65) N,N-Dipropyltryptamine (DPT);
9.5(66) 3-[1-(Piperidin-1-yl)cyclohexyl]phenol (3-HO-PCP);
9.6(67) N-ethyl-1-(3-methoxyphenyl)cyclohexanamine (3-MeO-PCE);
9.7(68) 4-[1-(3-methoxyphenyl)cyclohexyl]morpholine (3-MeO-PCMo);
9.8(69) 1-[1-(4-methoxyphenyl)cyclohexyl]-piperidine (methoxydine, 4-MeO-PCP);
9.9(70) 2-(2-Chlorophenyl)-2-(ethylamino)cyclohexan-1-one (N-Ethylnorketamine,
9.10ethketamine, NENK);
9.11(71) methylenedioxy-N,N-dimethylamphetamine (MDDMA);
9.12(72) 3-(2-Ethyl(methyl)aminoethyl)-1H-indol-4-yl (4-AcO-MET); and
9.13(73) 2-Phenyl-2-(methylamino)cyclohexanone (deschloroketamine).
9.14(e) Peyote. All parts of the plant presently classified botanically as Lophophora
williamsii
9.15Lemaire, whether growing or not, the seeds thereof, any extract from any part of the
plant,
9.16and every compound, manufacture, salts, derivative, mixture, or preparation of the
plant,
9.17its seeds or extracts. The listing of peyote as a controlled substance in Schedule
I does not
9.18apply to the nondrug use of peyote in bona fide religious ceremonies of the American
Indian
9.19Church, and members of the American Indian Church are exempt from registration. Any
9.20person who manufactures peyote for or distributes peyote to the American Indian Church,
9.21however, is required to obtain federal registration annually and to comply with all
other
9.22requirements of law.
9.23(f) Central nervous system depressants. Unless specifically excepted or unless listed
in
9.24another schedule, any material compound, mixture, or preparation which contains any
9.25quantity of the following substances, their analogs, salts, isomers, and salts of
isomers
9.26whenever the existence of the analogs, salts, isomers, and salts of isomers is possible:
9.27(1) mecloqualone;
9.28(2) methaqualone;
9.29(3) gamma-hydroxybutyric acid (GHB), including its esters and ethers;
9.30(4) flunitrazepam;
10.1(5) 2-(2-Methoxyphenyl)-2-(methylamino)cyclohexanone (2-MeO-2-deschloroketamine,
10.2methoxyketamine);
10.3(6) tianeptine;
10.4(7) clonazolam;
10.5(8) etizolam;
10.6(9) flubromazolam; and
10.7(10) flubromazepam.
10.8(g) Stimulants. Unless specifically excepted or unless listed in another schedule,
any
10.9material compound, mixture, or preparation which contains any quantity of the following
10.10substances, their analogs, salts, isomers, and salts of isomers whenever the existence
of the
10.11analogs, salts, isomers, and salts of isomers is possible:
10.12 (1) aminorex;
10.13(2) cathinone;
10.14(3) fenethylline;
10.15 (4) methcathinone;
10.16(5) methylaminorex;
10.17(6) N,N-dimethylamphetamine;
10.18(7) N-benzylpiperazine (BZP);
10.19(8) methylmethcathinone (mephedrone);
10.20(9) 3,4-methylenedioxy-N-methylcathinone (methylone);
10.21(10) methoxymethcathinone (methedrone);
10.22(11) methylenedioxypyrovalerone (MDPV);
10.23(12) 3-fluoro-N-methylcathinone (3-FMC);
10.24(13) methylethcathinone (MEC);
10.25(14) 1-benzofuran-6-ylpropan-2-amine (6-APB);
10.26(15) dimethylmethcathinone (DMMC);
10.27(16) fluoroamphetamine;
10.28(17) fluoromethamphetamine;
11.1(18) α-methylaminobutyrophenone (MABP or buphedrone);
11.2(19) 1-(1,3-benzodioxol-5-yl)-2-(methylamino)butan-1-one (butylone);
11.3(20) 2-(methylamino)-1-(4-methylphenyl)butan-1-one (4-MEMABP or BZ-6378);
11.4(21) 1-(naphthalen-2-yl)-2-(pyrrolidin-1-yl) pentan-1-one (naphthylpyrovalerone or
11.5naphyrone);
11.6(22) (alpha-pyrrolidinopentiophenone (alpha-PVP);
11.7(23) (RS)-1-(4-methylphenyl)-2-(1-pyrrolidinyl)-1-hexanone (4-Me-PHP or MPHP);
11.8(24) 2-(1-pyrrolidinyl)-hexanophenone (Alpha-PHP);
11.9(25) 4-methyl-N-ethylcathinone (4-MEC);
11.10(26) 4-methyl-alpha-pyrrolidinopropiophenone (4-MePPP);
11.11(27) 2-(methylamino)-1-phenylpentan-1-one (pentedrone);
11.12(28) 1-(1,3-benzodioxol-5-yl)-2-(methylamino)pentan-1-one (pentylone);
11.13(29) 4-fluoro-N-methylcathinone (4-FMC);
11.14(30) 3,4-methylenedioxy-N-ethylcathinone (ethylone);
11.15(31) alpha-pyrrolidinobutiophenone (α-PBP);
11.16(32) 5-(2-Aminopropyl)-2,3-dihydrobenzofuran (5-APDB);
11.17(33) 1-phenyl-2-(1-pyrrolidinyl)-1-heptanone (PV8);
11.18(34) 6-(2-Aminopropyl)-2,3-dihydrobenzofuran (6-APDB);
11.19(35) 4-methyl-alpha-ethylaminopentiophenone (4-MEAPP);
11.20(36) 4'-chloro-alpha-pyrrolidinopropiophenone (4'-chloro-PPP);
11.21(37) 1-(1,3-Benzodioxol-5-yl)-2-(dimethylamino)butan-1-one (dibutylone, bk-DMBDB);
11.22(38) 1-(3-chlorophenyl) piperazine (meta-chlorophenylpiperazine or mCPP);
11.23(39) 1-(1,3-benzodioxol-5-yl)-2-(ethylamino)-pentan-1-one (N-ethylpentylone, ephylone);
11.24and
11.25(40) any other substance, except bupropion or compounds listed under a different
11.26schedule, that is structurally derived from 2-aminopropan-1-one by substitution at
the
11.271-position with either phenyl, naphthyl, or thiophene ring systems, whether or not
the
11.28compound is further modified in any of the following ways:
12.1(i) by substitution in the ring system to any extent with alkyl, alkylenedioxy, alkoxy,
12.2haloalkyl, hydroxyl, or halide substituents, whether or not further substituted in
the ring
12.3system by one or more other univalent substituents;
12.4(ii) by substitution at the 3-position with an acyclic alkyl substituent;
12.5(iii) by substitution at the 2-amino nitrogen atom with alkyl, dialkyl, benzyl, or
12.6methoxybenzyl groups; or
12.7(iv) by inclusion of the 2-amino nitrogen atom in a cyclic structure.
12.8(h)
Marijuana, Synthetic tetrahydrocannabinols
, and synthetic cannabinoids. Unless
12.9specifically excepted or unless listed in another schedule, any
natural or synthetic material,
12.10compound, mixture, or preparation that contains any quantity of the following substances,
12.11their analogs, isomers, esters, ethers, salts, and salts of isomers, esters, and ethers,
whenever
12.12the existence of the isomers, esters, ethers, or salts is possible:
12.13(1) marijuana;
12.14(2) (1) synthetic tetrahydrocannabinols
naturally contained in a plant of the genus
12.15Cannabis, that are the synthetic equivalents of the substances contained in the cannabis
12.16plant or in the resinous extractives of the plant, or synthetic substances with similar
chemical
12.17structure and pharmacological activity to those substances contained in the plant
or resinous
12.18extract, including, but not limited to, 1 cis or trans tetrahydrocannabinol, 6 cis
or trans
12.19tetrahydrocannabinol, and 3,4 cis or trans tetrahydrocannabinol;
and
12.20(3) (2) synthetic cannabinoids, including the following substances:
12.21(i) Naphthoylindoles, which are any compounds containing a 3-(1-napthoyl)indole
12.22structure with substitution at the nitrogen atom of the indole ring by an alkyl, haloalkyl,
12.23alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl or
12.242-(4-morpholinyl)ethyl group, whether or not further substituted in the indole ring
to any
12.25extent and whether or not substituted in the naphthyl ring to any extent. Examples
of
12.26naphthoylindoles include, but are not limited to:
12.27(A) 1-Pentyl-3-(1-naphthoyl)indole (JWH-018 and AM-678);
12.28(B) 1-Butyl-3-(1-naphthoyl)indole (JWH-073);
12.29(C) 1-Pentyl-3-(4-methoxy-1-naphthoyl)indole (JWH-081);
12.30(D) 1-[2-(4-morpholinyl)ethyl]-3-(1-naphthoyl)indole (JWH-200);
12.31(E) 1-Propyl-2-methyl-3-(1-naphthoyl)indole (JWH-015);
13.1(F) 1-Hexyl-3-(1-naphthoyl)indole (JWH-019);
13.2(G) 1-Pentyl-3-(4-methyl-1-naphthoyl)indole (JWH-122);
13.3(H) 1-Pentyl-3-(4-ethyl-1-naphthoyl)indole (JWH-210);
13.4(I) 1-Pentyl-3-(4-chloro-1-naphthoyl)indole (JWH-398);
13.5(J) 1-(5-fluoropentyl)-3-(1-naphthoyl)indole (AM-2201).
13.6(ii) Napthylmethylindoles, which are any compounds containing a
13.71H-indol-3-yl-(1-naphthyl)methane structure with substitution at the nitrogen atom
of the
13.8indole ring by an alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl,
13.91-(N-methyl-2-piperidinyl)methyl or 2-(4-morpholinyl)ethyl group, whether or not further
13.10substituted in the indole ring to any extent and whether or not substituted in the
naphthyl
13.11ring to any extent. Examples of naphthylmethylindoles include, but are not limited
to:
13.12(A) 1-Pentyl-1H-indol-3-yl-(1-naphthyl)methane (JWH-175);
13.13(B) 1-Pentyl-1H-indol-3-yl-(4-methyl-1-naphthyl)methane (JWH-184).
13.14(iii) Naphthoylpyrroles, which are any compounds containing a 3-(1-naphthoyl)pyrrole
13.15structure with substitution at the nitrogen atom of the pyrrole ring by an alkyl,
haloalkyl,
13.16alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl or
13.172-(4-morpholinyl)ethyl group whether or not further substituted in the pyrrole ring
to any
13.18extent, whether or not substituted in the naphthyl ring to any extent. Examples of
13.19naphthoylpyrroles include, but are not limited to,
13.20(5-(2-fluorophenyl)-1-pentylpyrrol-3-yl)-naphthalen-1-ylmethanone (JWH-307).
13.21(iv) Naphthylmethylindenes, which are any compounds containing a naphthylideneindene
13.22structure with substitution at the 3-position of the indene ring by an alkyl, haloalkyl,
alkenyl,
13.23cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl or
13.242-(4-morpholinyl)ethyl group whether or not further substituted in the indene ring
to any
13.25extent, whether or not substituted in the naphthyl ring to any extent. Examples of
13.26naphthylemethylindenes include, but are not limited to,
13.27E-1-[1-(1-naphthalenylmethylene)-1H-inden-3-yl]pentane (JWH-176).
13.28(v) Phenylacetylindoles, which are any compounds containing a 3-phenylacetylindole
13.29structure with substitution at the nitrogen atom of the indole ring by an alkyl, haloalkyl,
13.30alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl or
13.312-(4-morpholinyl)ethyl group whether or not further substituted in the indole ring
to any
13.32extent, whether or not substituted in the phenyl ring to any extent. Examples of
13.33phenylacetylindoles include, but are not limited to:
14.1(A) 1-(2-cyclohexylethyl)-3-(2-methoxyphenylacetyl)indole (RCS-8);
14.2(B) 1-pentyl-3-(2-methoxyphenylacetyl)indole (JWH-250);
14.3(C) 1-pentyl-3-(2-methylphenylacetyl)indole (JWH-251);
14.4(D) 1-pentyl-3-(2-chlorophenylacetyl)indole (JWH-203).
14.5(vi) Cyclohexylphenols, which are compounds containing a
14.62-(3-hydroxycyclohexyl)phenol structure with substitution at the 5-position of the
phenolic
14.7ring by an alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl,
14.81-(N-methyl-2-piperidinyl)methyl or 2-(4-morpholinyl)ethyl group whether or not substituted
14.9in the cyclohexyl ring to any extent. Examples of cyclohexylphenols include, but are
not
14.10limited to:
14.11(A) 5-(1,1-dimethylheptyl)-2-[(1R,3S)-3-hydroxycyclohexyl]-phenol (CP 47,497);
14.12(B) 5-(1,1-dimethyloctyl)-2-[(1R,3S)-3-hydroxycyclohexyl]-phenol
14.13(Cannabicyclohexanol or CP 47,497 C8 homologue);
14.14(C) 5-(1,1-dimethylheptyl)-2-[(1R,2R)-5-hydroxy-2-(3-hydroxypropyl)cyclohexyl]
14.15-phenol (CP 55,940).
14.16(vii) Benzoylindoles, which are any compounds containing a 3-(benzoyl)indole structure
14.17with substitution at the nitrogen atom of the indole ring by an alkyl, haloalkyl,
alkenyl,
14.18cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl or
14.192-(4-morpholinyl)ethyl group whether or not further substituted in the indole ring
to any
14.20extent and whether or not substituted in the phenyl ring to any extent. Examples of
14.21benzoylindoles include, but are not limited to:
14.22(A) 1-Pentyl-3-(4-methoxybenzoyl)indole (RCS-4);
14.23(B) 1-(5-fluoropentyl)-3-(2-iodobenzoyl)indole (AM-694);
14.24(C) (4-methoxyphenyl-[2-methyl-1-(2-(4-morpholinyl)ethyl)indol-3-yl]methanone (WIN
14.2548,098 or Pravadoline).
14.26(viii) Others specifically named:
14.27(A) (6aR,10aR)-9-(hydroxymethyl)-6,6-dimethyl-3-(2-methyloctan-2-yl)
14.28-6a,7,10,10a-tetrahydrobenzo[c]chromen-1-ol (HU-210);
14.29(B) (6aS,10aS)-9-(hydroxymethyl)-6,6-dimethyl-3-(2-methyloctan-2-yl)
14.30-6a,7,10,10a-tetrahydrobenzo[c]chromen-1-ol (Dexanabinol or HU-211);
15.1(C) 2,3-dihydro-5-methyl-3-(4-morpholinylmethyl)pyrrolo[1,2,3-de]
15.2-1,4-benzoxazin-6-yl-1-naphthalenylmethanone (WIN 55,212-2);
15.3(D) (1-pentylindol-3-yl)-(2,2,3,3-tetramethylcyclopropyl)methanone (UR-144);
15.4(E) (1-(5-fluoropentyl)-1H-indol-3-yl)(2,2,3,3-tetramethylcyclopropyl)methanone
15.5(XLR-11);
15.6(F) 1-pentyl-N-tricyclo[3.3.1.13,7]dec-1-yl-1H-indazole-3-carboxamide
15.7(AKB-48(APINACA));
15.8(G) N-((3s,5s,7s)-adamantan-1-yl)-1-(5-fluoropentyl)-1H-indazole-3-carboxamide
15.9(5-Fluoro-AKB-48);
15.10(H) 1-pentyl-8-quinolinyl ester-1H-indole-3-carboxylic acid (PB-22);
15.11(I) 8-quinolinyl ester-1-(5-fluoropentyl)-1H-indole-3-carboxylic acid (5-Fluoro PB-22);
15.12(J) N-[(1S)-1-(aminocarbonyl)-2-methylpropyl]-1-pentyl-1H-indazole- 3-carboxamide
15.13(AB-PINACA);
15.14(K) N-[(1S)-1-(aminocarbonyl)-2-methylpropyl]-1-[(4-fluorophenyl)methyl]-
15.151H-indazole-3-carboxamide (AB-FUBINACA);
15.16(L) N-[(1S)-1-(aminocarbonyl)-2-methylpropyl]-1-(cyclohexylmethyl)-1H-
15.17indazole-3-carboxamide(AB-CHMINACA);
15.18(M) (S)-methyl 2-(1-(5-fluoropentyl)-1H-indazole-3-carboxamido)-3- methylbutanoate
15.19(5-fluoro-AMB);
15.20(N) [1-(5-fluoropentyl)-1H-indazol-3-yl](naphthalen-1-yl) methanone (THJ-2201);
15.21(O) (1-(5-fluoropentyl)-1H-benzo[d]imidazol-2-yl)(naphthalen-1-yl)methanone)
15.22(FUBIMINA);
15.23(P) (7-methoxy-1-(2-morpholinoethyl)-N-((1S,2S,4R)-1,3,3-trimethylbicyclo
15.24[2.2.1]heptan-2-yl)-1H-indole-3-carboxamide (MN-25 or UR-12);
15.25(Q) (S)-N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-(5-fluoropentyl)
15.26-1H-indole-3-carboxamide (5-fluoro-ABICA);
15.27(R) N-(1-amino-3-phenyl-1-oxopropan-2-yl)-1-(5-fluoropentyl)
15.28-1H-indole-3-carboxamide;
15.29(S) N-(1-amino-3-phenyl-1-oxopropan-2-yl)-1-(5-fluoropentyl)
15.30-1H-indazole-3-carboxamide;
16.1(T) methyl 2-(1-(cyclohexylmethyl)-1H-indole-3-carboxamido) -3,3-dimethylbutanoate;
16.2(U) N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1(cyclohexylmethyl)-1
16.3H-indazole-3-carboxamide (MAB-CHMINACA);
16.4(V) N-(1-Amino-3,3-dimethyl-1-oxo-2-butanyl)-1-pentyl-1H-indazole-3-carboxamide
16.5(ADB-PINACA);
16.6(W) methyl (1-(4-fluorobenzyl)-1H-indazole-3-carbonyl)-L-valinate (FUB-AMB);
16.7(X) N-[(1S)-2-amino-2-oxo-1-(phenylmethyl)ethyl]-1-(cyclohexylmethyl)-1H-Indazole-
16.83-carboxamide. (APP-CHMINACA);
16.9(Y) quinolin-8-yl 1-(4-fluorobenzyl)-1H-indole-3-carboxylate (FUB-PB-22); and
16.10(Z) methyl N-[1-(cyclohexylmethyl)-1H-indole-3-carbonyl]valinate (MMB-CHMICA).
16.11(ix) Additional substances specifically named:
16.12(A) 1-(5-fluoropentyl)-N-(2-phenylpropan-2-yl)-1
16.13H-pyrrolo[2,3-B]pyridine-3-carboxamide (5F-CUMYL-P7AICA);
16.14(B) 1-(4-cyanobutyl)-N-(2- phenylpropan-2-yl)-1 H-indazole-3-carboxamide
16.15(4-CN-Cumyl-Butinaca);
16.16(C) naphthalen-1-yl-1-(5-fluoropentyl)-1-H-indole-3-carboxylate (NM2201; CBL2201);
16.17(D) N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-(5-fluoropentyl)-1
16.18H-indazole-3-carboxamide (5F-ABPINACA);
16.19(E) methyl-2-(1-(cyclohexylmethyl)-1H-indole-3-carboxamido)-3,3-dimethylbutanoate
16.20(MDMB CHMICA);
16.21(F) methyl 2-(1-(5-fluoropentyl)-1H-indazole-3-carboxamido)-3,3-dimethylbutanoate
16.22(5F-ADB; 5F-MDMB-PINACA); and
16.23(G) N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-(4-fluorobenzyl)
16.241H-indazole-3-carboxamide (ADB-FUBINACA).
16.25(i) A controlled substance analog, to the extent that it is implicitly or explicitly
intended
16.26for human consumption.
16.27EFFECTIVE DATE.This section is effective August 1, 2022, and applies to crimes
16.28committed on or after that date.
16.29 Sec. 28. Minnesota Statutes 2020, section 152.02, subdivision 3, is amended to read:
16.30 Subd. 3.
Schedule II. (a) Schedule II consists of the substances listed in this subdivision.
17.1(b) Unless specifically excepted or unless listed in another schedule, any of the
following
17.2substances whether produced directly or indirectly by extraction from substances of
vegetable
17.3origin or independently by means of chemical synthesis, or by a combination of extraction
17.4and chemical synthesis:
17.5(1) Opium and opiate, and any salt, compound, derivative, or preparation of opium
or
17.6opiate.
17.7(i) Excluding:
17.8(A) apomorphine;
17.9(B) thebaine-derived butorphanol;
17.10(C) dextrophan;
17.11(D) nalbuphine;
17.12(E) nalmefene;
17.13(F) naloxegol;
17.14(G) naloxone;
17.15(H) naltrexone; and
17.16(I) their respective salts;
17.17(ii) but including the following:
17.18(A) opium, in all forms and extracts;
17.19(B) codeine;
17.20(C) dihydroetorphine;
17.21(D) ethylmorphine;
17.22(E) etorphine hydrochloride;
17.23(F) hydrocodone;
17.24(G) hydromorphone;
17.25(H) metopon;
17.26(I) morphine;
17.27(J) oxycodone;
17.28(K) oxymorphone;
18.1(L) thebaine;
18.2(M) oripavine;
18.3(2) any salt, compound, derivative, or preparation thereof which is chemically equivalent
18.4or identical with any of the substances referred to in clause (1), except that these
substances
18.5shall not include the isoquinoline alkaloids of opium;
18.6(3) opium poppy and poppy straw;
18.7(4) coca leaves and any salt, cocaine compound, derivative, or preparation of coca
leaves
18.8(including cocaine and ecgonine and their salts, isomers, derivatives, and salts of
isomers
18.9and derivatives), and any salt, compound, derivative, or preparation thereof which
is
18.10chemically equivalent or identical with any of these substances, except that the substances
18.11shall not include decocainized coca leaves or extraction of coca leaves, which extractions
18.12do not contain cocaine or ecgonine;
18.13(5) concentrate of poppy straw (the crude extract of poppy straw in either liquid,
solid,
18.14or powder form which contains the phenanthrene alkaloids of the opium poppy).
18.15(c) Any of the following opiates, including their isomers, esters, ethers, salts,
and salts
18.16of isomers, esters and ethers, unless specifically excepted, or unless listed in another
schedule,
18.17whenever the existence of such isomers, esters, ethers and salts is possible within
the specific
18.18chemical designation:
18.19(1) alfentanil;
18.20(2) alphaprodine;
18.21(3) anileridine;
18.22(4) bezitramide;
18.23(5) bulk dextropropoxyphene (nondosage forms);
18.24(6) carfentanil;
18.25(7) dihydrocodeine;
18.26(8) dihydromorphinone;
18.27(9) diphenoxylate;
18.28(10) fentanyl;
18.29(11) isomethadone;
18.30(12) levo-alpha-acetylmethadol (LAAM);
19.1(13) levomethorphan;
19.2(14) levorphanol;
19.3(15) metazocine;
19.4(16) methadone;
19.5(17) methadone - intermediate, 4-cyano-2-dimethylamino-4, 4-diphenylbutane;
19.6(18) moramide - intermediate, 2-methyl-3-morpholino-1, 1-diphenyl-propane-carboxylic
19.7acid;
19.8(19) pethidine;
19.9(20) pethidine - intermediate - a, 4-cyano-1-methyl-4-phenylpiperidine;
19.10(21) pethidine - intermediate - b, ethyl-4-phenylpiperidine-4-carboxylate;
19.11(22) pethidine - intermediate - c, 1-methyl-4-phenylpiperidine-4-carboxylic acid;
19.12(23) phenazocine;
19.13(24) piminodine;
19.14(25) racemethorphan;
19.15(26) racemorphan;
19.16(27) remifentanil;
19.17(28) sufentanil;
19.18(29) tapentadol;
19.19(30) 4-Anilino-N-phenethylpiperidine.
19.20(d) Unless specifically excepted or unless listed in another schedule, any material,
19.21compound, mixture, or preparation which contains any quantity of the following substances
19.22having a stimulant effect on the central nervous system:
19.23(1) amphetamine, its salts, optical isomers, and salts of its optical isomers;
19.24(2) methamphetamine, its salts, isomers, and salts of its isomers;
19.25(3) phenmetrazine and its salts;
19.26(4) methylphenidate;
19.27(5) lisdexamfetamine.
20.1(e) Unless specifically excepted or unless listed in another schedule, any material,
20.2compound, mixture, or preparation which contains any quantity of the following substances
20.3having a depressant effect on the central nervous system, including its salts, isomers,
and
20.4salts of isomers whenever the existence of such salts, isomers, and salts of isomers
is possible
20.5within the specific chemical designation:
20.6(1) amobarbital;
20.7(2) glutethimide;
20.8(3) secobarbital;
20.9(4) pentobarbital;
20.10(5) phencyclidine;
20.11(6) phencyclidine immediate precursors:
20.12(i) 1-phenylcyclohexylamine;
20.13(ii) 1-piperidinocyclohexanecarbonitrile;
20.14(7) phenylacetone.
20.15(f)
Cannabis and cannabinoids:
20.16(1) nabilone;
20.17(2) unless specifically excepted or unless listed in another schedule, any natural
material,
20.18compound, mixture, or preparation that contains any quantity of the following substances,
20.19their analogs, isomers, esters, ethers, salts, and salts of isomers, esters, and ethers,
whenever
20.20the existence of the isomers, esters, ethers, or salts is possible:
20.21(i) marijuana; and
20.22(ii) tetrahydrocannabinols naturally contained in a plant of the genus cannabis or
in the
20.23resinous extractives of the plant, except that a product containing tetrahydrocannabinols
is
20.24not included if it meets the requirements of section 151.72; and
20.25(2) (3) dronabinol [(-)-delta-9-trans-tetrahydrocannabinol (delta-9-THC)] in an oral
20.26solution in a drug product approved for marketing by the United States Food and Drug
20.27Administration.
20.28EFFECTIVE DATE.This section is effective August 1, 2022, and applies to crimes
20.29committed on or after that date.
21.1 Sec. 29. Minnesota Statutes 2020, section 152.11, is amended by adding a subdivision to
21.2read:
21.3 Subd. 5. Exception. References in this section to Schedule II controlled substances do
21.4not extend to marijuana or tetrahydrocannabinols.
21.5 Sec. 30. Minnesota Statutes 2020, section 152.12, is amended by adding a subdivision to
21.6read:
21.7 Subd. 6. Exception. References in this section to Schedule II controlled substances do
21.8not extend to marijuana or tetrahydrocannabinols."
21.9Renumber the sections in sequence and correct the internal references
21.10Amend the title accordingly
21.11The motion prevailed. #did not prevail. So the amendment was #not adopted.